NDAINJECTIONINJECTABLE
Approved
Oct 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
UREAPHIL (urea) by Pfizer. Approved for type 2 diabetes mellitus, polycythemia vera, essential thrombocythemia and 18 more indications. First approved in 1966.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UREAPHIL (urea) is an injectable small molecule approved in 1966 for multiple indications spanning endocrine, hematologic, oncologic, dermatologic, and infectious disease areas. The product treats diverse conditions including Type 2 Diabetes, polycythemia vera, glioblastoma, atopic dermatitis, sickle cell disease, and HIV infection. Mechanism of action and pharmacologic class data are not available in current records.
LOE Approaching
With LOE approaching and limited commercial data, the brand team is likely focused on defensive strategies and cost-optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on UREAPHIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.